FIELD: medicine.
SUBSTANCE: patient's peripheral venous blood is sampled in the amount of 10 ml; patient's peripheral blood 5 ml is centrifuged at density gradient ρ=1.077, and another 5 ml of peripheral blood of the same patient are ultra-centrifuged. Mononuclear and endothelial cell fractions are placed in the related cultivation bottles. The cells adherent to the bottle surface are dissociated and counted up in a Goryaev chamber. The cell count is divided into a number of the counted up squares, multiplied by 1000 that corresponds to the content of the primary endothelial progenitor cells or the specialised endothelial progenitor cells at 5 ml of blood. If the primary endothelial progenitor cell count exceeds the specialised endothelial progenitor cell count in 20 times and more, the absence of endothelial dysfunction is stated - ED0. If the primary endothelial progenitor cell count exceeds the specialised endothelial progenitor cell count in 5 to 20 times, high reparative ability of vascular endotheliocytes and preserving function of endotheliocytes, physiological endothelial dysfunction is stated, EDf. If the primary endothelial progenitor cell count exceeds the specialised endothelial progenitor cell count in 2 to 5 times, a sufficient reparative ability of vascular endothelium and relative preserving function of endotheliocytes are stated, ED I. The primary endothelial progenitor cell count related to the specialised endothelial progenitor cell count as 1:1.0-1.4 or 1.5:1 shows moderate endothelial dysfunction and the preserving preparative ability of an endothelial layer - ED II. The primary endothelial progenitor cell count related to the specialised endothelial progenitor cell count as 1:≥1.5 enables to consider evident endothelial dysfunction with the severely impaired preparative ability of the endothelium - ED III.
EFFECT: use of the declared method allows both detecting the endothelial dysfunction, diagnosing a severity level, both assessing the repairative ability of the vascular wall that has a significant prognostic and therapeutic value.
3 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING BLOOD FLOW STATE IN HEALTHY INDIVIDUALS WITH CARDIOVASCULAR RISK FACTORS AND IN CARDIOVASCULAR PATIENTS | 2012 |
|
RU2508900C1 |
METHOD OF ESTIMATING EFFICACY OF VASCULAR THERAPY BY ENDOTHELIAL DYSFUNCTION INTENSITY | 2011 |
|
RU2455641C1 |
METHOD FOR EVALUATING LYMPHOCYTE EFFECT ON DEVELOPING ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2482487C2 |
DIAGNOSTIC TECHNIQUE FOR ENDOTHELIAL DYSFUNCTION IN PREGNANT WOMEN | 2020 |
|
RU2743851C1 |
METHOD FOR DIAGNOSIS OF ENDOTHELIAL DYSFUNCTION IN WOMEN | 2002 |
|
RU2234094C2 |
METHOD FOR PREDICTION OF RISK OF ARTERIAL HYPERTENSION DEVELOPMENT AND PROGRESS IN PATIENTS WITH CHRONIC HEPATITIS AT ANTI-VIRAL THERAPY BACKGROUND | 2016 |
|
RU2623793C2 |
METHOD FOR DIAGNOSIS OF TRAUMATIC ENDOTHELIAL DYSFUNCTION IN COMBINED SHOCK-PRODUCING TRAUMA | 2021 |
|
RU2782135C1 |
METHOD FOR DIAGNOSING ENDOTHELIAL DYSFUNCTION IN SMOKING PREGNANT WOMEN WITH ARTERIAL HYPERTENSION | 2021 |
|
RU2767927C1 |
METHOD OF EVALUATION OF DEGREE OF ENDOTHELIAL DYSFUNCTION | 2007 |
|
RU2324939C1 |
METHOD FOR EVALUATING CEREBRAL BLOOD VESSEL WALL INJURIES IN PATIENTS SUFFERED FROM INTRACRANIAL HEMORRHAGES | 2002 |
|
RU2239835C2 |
Authors
Dates
2012-06-20—Published
2011-02-28—Filed